Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of common stock, $0.0001 par value per share ("Common Stock") of Channel Therapeutics Corporation (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 6,028,011 shares of Common Stock of the Issuer outstanding as of November 11, 2024, as disclosed in the Issuer's prospectus filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of Common Stock of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 6,028,011 shares of Common Stock of the Issuer outstanding as of November 11, 2024, as disclosed in the Issuer's prospectus filed with the SEC on November 13, 2024.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:02/14/2025
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:02/14/2025